Precision treatment trial for children with advanced neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger when first diagnosed
- Your diagnosis must be neuroblastoma or ganglioneuroblastoma confirmed by lab tests on tumor tissue or bone marrow
- You must fit the trial’s specific risk group and stage rules (especially for advanced/high-risk disease)
- Before starting, you must meet key organ-function tests (heart, liver, kidneys)
- You generally can’t have had much prior whole-body treatment (with limited exceptions like emergency radiation or very limited chemotherapy)
- You must be able to safely collect blood stem cells if this is planned (based on your health and size)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.